Manuka Eye Droops for Treatment of Allergy

Status Withdrawn

Clinical Trial Summary

Manuka honey eye drops are used for dry eyes and blepharitis. Manuka honey has been proven to be useful for eczema, atopic dermatitis, wound healing, anti-bacterial, anti-parasitic and anti-inflammatory actions.

Clinical Trial Description

Ocular allergy is a condition that can affect a patient's quality of life. Symptoms of ocular allergy include but are not limited to red, itchy, swollen, foreign body sensation, watery, puffy or blurry eyes. irritation, redness, burning, foreign body sensation, dryness, pain and blurry vision. In many cases, ocular allergic conjunctivitis are due to seasonal allergens like pollen, mold or indoor allergens such as pet dander or dust mites.

Ocular allergy can be treated by avoidance of known allergens, reduction of allergens by use of HEPA filters, cleaning linens, etc, topical decongestants, over the counter and prescription topical non-steroidals, topical or oral antihistamines, mast cell stabilizers or topical or oral steroids.

Manuka honey is produced by bees that are associated with the flowers of the Manuka plant (Leptospermum scoparium) that grows in New Zealand. Manuka honey is different from other honeys because it has been shown to the more potent due to its higher methylglyoxal concentration.

Manuka honey has been used for its anti-oxidant, anti-bacteral and anti-inflammatory properties. It has been shown to be useful in healing eczematous skin lesions. This study will attempt to demonstrate topical anti-allergy use for ocular allergy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03862053
Study type	Interventional
Source	Toyos Clinic
Contact
Status	Withdrawn
Phase	Phase 4
Start date	January 1, 2020
Completion date	October 7, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03660878` - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis	Phase 1/Phase 2
Completed	`NCT03682965` - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study	Phase 2
Completed	`NCT01697969` - Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT01685242` - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle	Phase 3
Completed	`NCT01439815` - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo	Phase 4
Completed	`NCT01294969` - Patient Perception Study for AL-4943A	Phase 4
Completed	`NCT01471184` - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo	Phase 1
Completed	`NCT00609128` - Effect of Olopatadine on Allergic Tear Mediators	N/A
Recruiting	`NCT05969236` - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults	Phase 1
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Not yet recruiting	`NCT01012752` - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts	Phase 3
Completed	`NCT01698814` - A Six-Week Safety Study of an Investigational Ophthalmic Solution	Phase 3
Completed	`NCT01754766` - AGN-229666 for the Treatment of Allergic Conjunctivitis	Phase 2
Completed	`NCT01443442` - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis	Phase 4
Completed	`NCT01203540` - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients	Phase 4
Completed	`NCT00987272` - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects	Phase 3
Completed	`NCT00769886` - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.	Phase 3
Completed	`NCT00586664` - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis	Phase 3
Completed	`NCT00534794` - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis	Phase 4
Completed	`NCT00569777` - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers	Phase 3